Peripheral Artery Disease
Real-world studies show no mortality signal related to paclitaxel-coated devices
Unlike with meta-analyses of randomized controlled trials, seven real-world studies of patients with peripheral artery disease have shown no long-term mortality signal related to use of paclitaxel-coated devices, a speaker said at the International Symposium on Endovascular Therapy.
LIBERTY 360°: Regardless of PAD severity, endovascular interventions helpful at 3 years
At 3 years, patients with various stages of peripheral artery disease who underwent endovascular interventions had high rates of freedom from adverse limb events, according to new data from the LIBERTY 360° study presented at the International Symposium on Endovascular Therapy.
Long-term mortality after CLI diagnosis high, urgent action needed
The 4-year mortality rate after a diagnosis of critical limb ischemia is more than 50%, comparable to the deadliest cancers, which demands a nationally coordinated action plan, a speaker said at the International Symposium on Endovascular Therapy.
Medical therapy beneficial in PAD, but underprescribed
There is now plentiful evidence that medical therapy benefits patients with peripheral artery disease, which is reflected in guidelines but not followed nearly enough, a speaker stated at the International Symposium on Endovascular Therapy.
Peripheral artery disease more common in patients with late-stage CKD
More than 2 million patients with CVD have reported marijuana use
Despite the modest strength of current evidence, cardiologists should screen and test their patients for marijuana use in select CV settings, according to a review published in the Journal of the American College of Cardiology.
Q&A: Additional therapies for secondary prevention may be effective, but also expensive
Results of a 5-year estimate showed that up to 20% of CV events could be prevented if patients with ischemic heart disease or MI received additional secondary prevention therapies that they are eligible for.
Meta-analysis: Paclitaxel-coated balloons may be harmful in below-the-knee lesions
A systematic review and study-level meta-analysis of randomized controlled trials of treatment of infrapopliteal arteries found that paclitaxel-coated balloons confer worse amputation-free survival compared with uncoated balloons.
Top stories from VIVA: Peripheral DES, drug-coated balloons and more
Healio and Cardiology Today present meeting highlights from VIVA 19 in Las Vegas. Top stories included the latest from the IMPERIAL head-to-head comparison of two peripheral drug-eluting stents, a low-dose paclitaxel-coated balloon, new advances for patients with critical limb ischemia and more.
Sirolimus-coated balloon benefit maintained at 2 years
LAS VEGAS — A sirolimus-coated balloon for treatment of peripheral artery disease was associated with positive outcomes at 2 years, according to new data from the SELUTION study presented at VIVA 19.